Figures & data
Figure 1 Disease characteristics among subject population.
Abbreviations: PAC, primary angle-closure; PACG, primary angle-closure glaucoma; POAG, primary open-angle glaucoma; OHT, ocular hypertension; NTG, normal-tension glaucoma.
![Figure 1 Disease characteristics among subject population.Abbreviations: PAC, primary angle-closure; PACG, primary angle-closure glaucoma; POAG, primary open-angle glaucoma; OHT, ocular hypertension; NTG, normal-tension glaucoma.](/cms/asset/8f47fc4d-0f69-4d5e-ac94-f109bf974e20/doph_a_12176435_f0001_c.jpg)
Table 1 Pre-study medication of patients switched to tafluprost (n=73)
Figure 2 Mean IOP change from baseline in mmHg and percentage (%) in all eyes treated with tafluprost 0.0015% with 0.001 BAK preservative. Primary endpoint was at 3 months. Bars represent standard deviation.
![Figure 2 Mean IOP change from baseline in mmHg and percentage (%) in all eyes treated with tafluprost 0.0015% with 0.001 BAK preservative. Primary endpoint was at 3 months. Bars represent standard deviation.](/cms/asset/7a37bb5b-0e89-456c-9867-ba86e2287324/doph_a_12176435_f0002_c.jpg)
Figure 3 Sub-group analysis based on therapeutic pattern. The treatment naïve subgroup had no previous glaucoma treatment. The add-on subgroup had tafluprost added to existing glaucoma medication to try to achieve further IOP reduction. The replacement subgroup had their glaucoma medication replaced with tafluprost. Primary endpoint was at 3 months. Bars represent standard deviation.
![Figure 3 Sub-group analysis based on therapeutic pattern. The treatment naïve subgroup had no previous glaucoma treatment. The add-on subgroup had tafluprost added to existing glaucoma medication to try to achieve further IOP reduction. The replacement subgroup had their glaucoma medication replaced with tafluprost. Primary endpoint was at 3 months. Bars represent standard deviation.](/cms/asset/474f0aee-10fb-4869-8755-ea56576fdc01/doph_a_12176435_f0003_c.jpg)
Figure 4 Sub-group analysis comparing degree of mean IOP reduction in eyes with primary open-angle glaucoma and ocular hypertension (POAG/OHT) sub-group compared to those with primary angle closure and primary angle-closure glaucoma post-laser iridotomy with at least 90 degrees open-angle (PAC/PACG) sub-group. Primary endpoint was at 3 months. Bars represent standard deviation.
![Figure 4 Sub-group analysis comparing degree of mean IOP reduction in eyes with primary open-angle glaucoma and ocular hypertension (POAG/OHT) sub-group compared to those with primary angle closure and primary angle-closure glaucoma post-laser iridotomy with at least 90 degrees open-angle (PAC/PACG) sub-group. Primary endpoint was at 3 months. Bars represent standard deviation.](/cms/asset/08cc3bde-003d-4b67-af42-9b5dcd573de2/doph_a_12176435_f0004_c.jpg)
Table 2 Adverse reactions recorded